The Evolution of the Hemophilia Treatment Landscape



Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, gives an overview of the different hemophilia therapies and recent improvements in the treatment landscape. 

Transcript

So the treatment landscape up until recently hadn’t changed much. They started off in the 60s with cryoprecipitate and then they were able to do factor concentrates in the 70s and 80s. That was a huge improvement for patients; they could actually treat themselves at home and not have to come to the hospital. And then of course the 1980s came, HIV and hepatitis devastated the community. And then there was a push to develop recombinant products, so the ones that were not developed from human plasma.
 
So there’s been an evolution but there really hasn’t been any significant change up until recently. They’ve extended the half-life of the products so it lasts a little longer in the body. But all the therapies up until just recently have been through IV therapies. So that means you would have to start an IV with a butterfly needle to get the therapy in. And as anybody knows, young children don’t like needles, that hasn’t changed. And so the new therapies are a different route. Subcutaneous is obviously a preferred route for some of these new therapies. Emicizumab particularly is a subcutaneous drug so that’s really changed the landscape. It’s only for hemophilia A.

Most Popular

Related Articles

Study finds that surgery was associated with a 44% increased chance of survival in patients with breast cancer, assuming the majority also had systemic treatment.
Chris Kepinski, PharmD, sat down with Specialty Pharmacy Times at the National Community Oncology Dispensing Association conference in Denver, Colorado to discuss how treatment support kits act a vital resource for patients throughout their treatment.
Aimmune’s Biologics License Application for AR101 under evaluation as a treatment to reduce the risk of anaphylaxis in peanut-allergic children and adolescents following exposure to peanut.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$